Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer.
Oncology
; 101(11): 738-752, 2023.
Article
em En
| MEDLINE
| ID: mdl-37651985
ABSTRACT
INTRODUCTION:
Personalized medicine and molecular therapies with the diagnosis of somatic genetic alterations are expected to be developed for liver cancer. Nevertheless, it is unknown whether a mutation in the telomere reverse transcriptase promoter (TERT C228T) in serum cfDNA might be useful for making prognostic predictions after surgical resection for primary liver cancer.METHODS:
This cohort study retrospectively investigated 111 patients who had undergone surgical resection of liver cancer for the first time. We investigated the differences between clinicopathological features and prognosis according to classification of three tumor markers, including AFP, PIVKAII, and TERT C228T.RESULTS:
Multivariate analysis identified etiology (fatty liver disease vs. HBV odds ratio [OR] 6.853) and fibrosis stage (2-4, OR 0.137) as determinants of TERT C228T-positive liver cancer with normal levels of AFP and PIVKAII (TERT single positive liver cancer). TERT single positive (Yes, OR 0.301), fibrosis (FIB)-4 index (≥3.25, OR 2.038), Child-Pugh classification (B, OR 4.975), and number of tumors (≥2, OR 4.098) were identified as determinants of the recurrence of liver cancer. TERT single positive (Yes, OR 3.311), FIB-4 index (≥3.25, OR 0.433), and number of tumors (≥2, OR 0.262) were identified as determinants of disease-free survival.CONCLUSIONS:
Our results highlight the impact of classification of prognostic tumor markers. TERT single positive is one predictor of favorable prognosis after surgical resection for liver cancer.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Oncology
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Japão